When the history of this century is written, it may record that artificial intelligence has captured the headlines along with venture capital and the anxieties of a generation. But the transformation of biology itself to Genome editing, synthetic biology, AI-assisted protein design and precision fermentation is turning living cells into reliable factories. For medicines, food, fuels and materials that until recently belonged exclusively to petrochemistry and heavy industry. NITI Aayog’s new roadmap, Building India as a Leading BioEconomy Powerhouse by 2035, is a national declaration that India means to be a maker of this new world, not by being only a consumer of it.
In just a decade, India’s bioeconomy has grown sixteen-fold, from a modest $10 billion in 2014 to $195.3 billion in 2025, now contributing 4.8 per cent of national GDP and expanding at nearly 18 per cent a year over the past four. The roadmap sets the next waypoints with unusual clarity of $392 billion by 2030, $691 billion by 2035 and $2.6 trillion by 2047, the year of Viksit Bharat. Along the way, it promises more than 30 million high-value jobs, over $100 billion in biotech exports, fifteen globally competitive biotech companies and a place among the world’s top three biotechnology powers. These are not the round, aspirational figures of a wish-list. They rest on a foundation that includes more than 10,000 biotech start-ups from barely 50 a decade ago. Over 700 USFDA-approved manufacturing plants, twenty-plus biosimilar products in global markets and a vaccine ecosystem the entire world leaned on during the pandemic.
The global race of BioEconomy
To understand why India’s approach is distinctive, it helps to see how the other major players are moving, because they are all moving fast. The World BioEconomy Forum projects the global bioeconomy surging from roughly $4 trillion in 2025 to over $30 trillion by 2050, nearly 13 per cent of an estimated $228 trillion world economy. The E7 economies, India among them, are forecast to lift their share of world GDP from about 35 per cent to nearly 50 per cent. The roadmap benchmarks the front-runners honestly, and the picture that emerges is of a race in which every serious economy has chosen a lane.
The United States, at roughly $950 billion today, has adopted a whole-of-government approach since 2022 in an Executive Order on Advancing Biotechnology and Biomanufacturing. Its preoccupation is unmistakably strategic with expanding domestic manufacturing capacity, hardening supply chains and coordinating federal muscle across health, energy, agriculture and security. Washington’s message is that scientific brilliance is no longer enough; production and standards are where power now lives. It is aiming at $3.5 trillion by 2040, with synthetic biology and AI-driven biology as its cutting edge.
The European Union, already the largest bloc at $2.6 trillion, has taken a different tack, threading the bioeconomy through its twin obsessions of industrial competitiveness and climate. Its 2025 Strategic Framework leans heavily on measurement systems, consistent indicators, circular-economy integration and regional delivery. The EU knew its genius and limitations; it excels at regulation and standards, and moves at the deliberate pace that consensus among twenty-seven members demands. Its target is $6 trillion by 2040.
China offers the sharpest contrast of all, a plan-led, state-directed industrial scale-up. Through its 14th Five-Year Plan for Bioeconomy Development, Beijing has designated biotechnology and biomanufacturing as strategic sectors and has wired them directly into national development priorities. It fused biosecurity governance with economic objectives. Regional pilot zones, manufacturing-led scale and a determination to reduce dependence on external supply chains define the model. From $500–600 billion today, China is reaching for $2 trillion by 2040, with gene editing and industrial enzymes as its spearheads.
Even mid-sized players such as Australia, at $65–80 billion, have found a niche by pursuing a translation-led industry-aligned path in which institutions like CSIRO bridge laboratory and market. What unites these very different strategies is one hard-won lesson the roadmap states plainly: leadership in the biological age will not flow from research alone. It flows from integrated systems that align capital, regulation, skills, data, infrastructure and manufacturing. It accrues disproportionately to those who move early. Everyone has read the same lesson. The question is what each nation does with it.
Where India’s path diverges from the rest countries
Here is the crux of the matter and the reason this roadmap is worth defending rather than merely summarising. India is not copying any of these models, and it would be a strategic error to try. Instead, the government has chosen a path that draws on India’s genuine and non-transferable advantages.
The organising framework is the BioE3 Policy — Biotechnology for Economy, Environment and Employment, which was approved in 2024. That third word, Employment, is quite important. The American approach is framed around security and reshoring, the European around sustainability and competitiveness, the Chinese around state power. India, alone among them, has explicitly welded its bioeconomy ambition to livelihoods.
The roadmap’s own phrase is “Lab to Market to Livelihood” an extension of the innovation chain to its social conclusion. In a country where a quarter of higher-education enrolment is already in STEM and 450,000 students are pursuing biotechnology, treating this frontier as a jobs engine as much as a technology is not sentimentality. It is strategic realism and the roadmap is candid that the cost of inaction includes forfeiting 30–35 million potential jobs in the fastest-growing deep-tech domain on earth, one compounding at 10–12 per cent globally.
The second pro is India’s starting position. No other rising power enters the biological age as the pharmacy of the world. India is already the largest vaccine manufacturer on earth and the trusted global supplier of affordable generics and biosimilars. When the roadmap speaks of leapfrogging from being the world’s most reliable source of affordable healthcare into the world’s “Bio-Capital,” it describes a jump only India is positioned to make because only India has both the manufacturing base and the credibility of having delivered at a population scale under extreme stress. Mission Covid Suraksha, which yielded five indigenous vaccines, including Zycov-D, Corbevax and Incovacc. It made the country Atmanirbhar in immunising its entire population, which was not a lucky improvisation. It was the payoff of four decades of patient institution-building since the 1983 Technology Policy Statement: the Department of Biotechnology, a BIRAC ecosystem that has backed over 4,500 innovators and 95-plus incubators to yield some 800 market products, the National Biopharma Mission that gave India Rotavac and Cervavac and most recently the Biotechnology Research and Innovation Council.
The third and most consequential difference lies in execution. Rather than a single sprawling strategy, the roadmap advances six focused National BioMissions, each with a ten-year horizon, ring-fenced budget and clear lead-ministry accountability. GeneIndia aims to make gene and cell therapies affordable, expanding GenomeIndia’s reference dataset to 50,000 and then one lakh individuals to target sickle cell disease, thalassaemia, haemophilia and SMA. AgriBio 2.0 pursues CRISPR-edited, climate-resilient crops and cleaner bio-inputs. BioX Foundry seeks to incubate at least 100 synthetic-biology start-ups through automated Design-Build-Test-Learn foundries. One Health Grid links human, animal and environmental surveillance across 23 BSL-3/4 laboratories against the next pandemic. Marine Biotechnology unlocks a $100-billion blue economy through seaweed. India hosts 844 species, some 60 of them commercially valuable, backed by ₹640 crore already committed under PMMSY. BioPharmaNext positions India as a hub for next-generation biologics. This is the mission-mode method that delivered Digital India and the vaccine effort, now redirected at biology.
The money, the rules and the people
An ambition of this magnitude is only as credible as the machinery behind it, and the roadmap is refreshingly concrete on the three fronts where good intentions usually go to die. On finance, the centrepiece is a proposed ₹50,000-crore (about $5.8 billion) BioEconomy Growth Fund for 2026–2035, embedded within the newly launched ₹1-lakh-crore RDI Scheme. Its explicit purpose is to close what the document represents the chasm between a working proof of concept and manufacturing at scale, where so many promising Indian ventures have starved for mid and late-stage capital. Coupled with a dedicated Production-Linked Incentive for biomanufacturing, modelled on the schemes that transformed pharmaceuticals and electronics, and the ₹10,000-crore Biopharma SHAKTI outlay, this is a serious attempt to convert laboratory excellence into export-driven industrial leadership. The commercial data shows that biosimilars are growing at 17 per cent a year with nearly ten times the return of stagnant generics, and $300 billion of blockbuster biopharmaceuticals go off-patent by 2030. Even a 1 per cent slice of the global biosimilar market could earn India roughly ₹6,400 crore annually.
On the regulation part, Indian approval timelines average around 900 days against roughly 500 in peer countries, and fragmented, multi-agency processes deter exactly the investment the country needs. Its answer is differentiated, risk-based pathways, regulatory sandboxes for frontier modalities such as cell and gene therapies and AI-designed drugs, a standing reform task force and a CDSCO modernised and benchmarked against the FDA, EMA and PMDA. This willingness to name a weakness and legislate against it is precisely the kind of governance that turns a policy document into a plan.
On the part of talent, honesty continues. India employs over 3.3 million professionals and supports nearly 12,000 start-ups, yet has only around 259 researchers per million people, a pipeline too thin to sustain leadership. The remedy is a decisive investment in bioscience education, internationally benchmarked fellowships, frontier skills in bioinformatics and AI-driven biology, re-entry pathways for diaspora scientists and a 100,000-strong allied health professionals pipeline under Biopharma SHAKTI. Investing in people as deliberately as in capital is how a demographic advantage becomes durable scientific strength.
An inclusive, not imitative model
What ultimately separates India’s approach from the American, European and Chinese templates is neither scale nor speed. It is intent. The US model is inward-looking by design, built for supply-chain security. The Chinese model is statist and, in parts, opaque. The European model is admirable but slow, weighed down by the very consensus that makes it coherent. India’s model aspires to be something the others are not, an open, affordable and inclusive bioeconomy that shapes markets and standards for itself while delivering solutions for the developing world that wealthy incumbents have little commercial incentive to serve. That is the difference worth insisting upon. When India commits to homegrown, affordable gene therapies for sickle cell disease or to bio-inputs that lift farmer incomes while cutting chemical dependence and advancing the E20 ethanol push, it is doing more than industrial policy. It is extending to the biological century the same civilisational proposition it brought to vaccines and digital public goods that the frontier need not be a privilege of the rich. India can evolve from the pharmacy of the world into the Innovation Engine of the World, delivering not just affordable copies but frontier breakthroughs on its own terms.
The cost of hesitation is spelt out with unusual bluntness: missed economic opportunity, deepened dependence on foreign biological solutions, a setback to the $30-trillion Viksit Bharat goal and the forfeiture of leadership in an age defined by biological mastery. Global competitors are not waiting, and first-mover advantages, once lost, are difficult to regain.
Roadmaps do not build biofoundries; execution does. But the strategic clarity on display here a distinctive model, an honest audit of weaknesses and a whole-of-government commitment to fixing them is exactly what the moment demands. The biological century will be shaped by those who act now and act fast. On the evidence of this roadmap, India has both the capability and at last this conviction will lead the world.
